Eribulin Mesylate Injection
Product Images NDC 10019-080

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 10019-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Eribulin Figure 1 (Eribulin Figure 1)

This text provides data on a clinical trial comparing Eribulin Mesylate Injection with a control group. The trial involved 508 patients in the Eribulin group and 254 patients in the control group. The graph shows the number of patients at risk over time in months, up to 36 months.*

FDA Label Image

Eribulin Structural Formula (Image 01)

FDA Label Image

Eribulin Figure 2 (Image 03)

Not available.*

FDA Label Image

Eribulin Baxter Logo (Image 04)

FDA Label Image

Patient Information Table Of Symptoms (Image 05)

This appears to be a list of symptoms including fever, cough, chills, and burning or pain during urination. These symptoms may indicate an infection or illness and should be evaluated by a healthcare professional.*

FDA Label Image

Patient Information Table Of Side Effects (1)

This text mentions symptoms related to low white and red blood cell counts, such as nausea and anemia with associated symptoms like constipation, weakness, tiredness, and hair loss (alopecia). These symptoms can be indicative of various health conditions that warrant further medical evaluation and management.*

FDA Label Image

Patient Information Table Of Side Effects (2)

This is a list of common symptoms that an individual may experience. Symptoms include tiredness, stomach pain, nausea, fever, hair loss (alopecia), and constipation. These symptoms can indicate various health issues and it is recommended to consult a healthcare professional for a proper evaluation and treatment.*

FDA Label Image

Eribulin Baxter Logo (Image 08)

FDA Label Image

Eriibulin Representative Container Label (NDC 10119-080-01)

This is a prescription information for Eribulin Mesylate Injection, a cytotoxic agent used for intravenous use in single-dose vials. It contains 1 mg/2 mL (0.5 mg/mL) of the sterile solution. The medication should not be frozen or refrigerated and should be stored at 25°C (77°F) with excursions permitted between 15°-30°C (59°-86°F). For dosage and usage guidelines, refer to the accompanying prescribing information. This product is distributed by Baxter Healthcare Corporation in Deerfield, Illinois, USA.*

FDA Label Image

Eribulin Representative Carton Label (NDC 10119-080-01 -1 of 2)

Description: This text provides information on a medication called Eribulin Mesylate Injection, a cytotoxic agent for intravenous use. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. It is recommended to discard any unused portion of the vial. The dosage and usage details are available in the accompanying prescribing information. The medication is stored at room temperature with excursions permitted to a specific range. It should not be frozen or refrigerated. Manufacturer details are also provided in the text.*

FDA Label Image

Eribulin Representative Carton Label (NDC 10119-080-01 -2 of 2)

This is prescription medication labeled as Eribulin Mesylate Injection, with a concentration of 1 mg/2 mg/2m for intravenous use. It is a sterile solution and a cytotoxic agent that comes in single-dose vials which should be discarded if unused. This product is distributed by Baxter Healthcare Corporation, based in Deerfield, IL, USA, and is a registered trademark of Baxter International Inc. Made in Germany.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.